Zacks Gives Neutral Rating to CME Group (CME)
CME Group (NYSE: CME)‘s stock had its “neutral” rating restated by Zacks in a report issued on Friday. They currently have a $288.00 target price on the stock.
CME Group opened at 268.38 on Friday. CME Group has a 52-week low of $224.69 and a 52-week high of $304.61. The company has a market cap of $17.832 billion and a price-to-earnings ratio of 9.89.
The company last announced its quarterly results on Thursday, April 26th. It reported $4.02 earnings per share (EPS) for the previous quarter, missing the Thomson Reuters consensus estimate of $4.03 EPS by $0.01. The company’s quarterly revenue was down 6.9% on a year-over-year basis. On average, analysts predict that CME Group will post $4.22 earnings per share next quarter.
Other equities research analysts have also recently issued reports about the stock. Analysts at Barclays Capital (NYSE: BCS) cut their price target on shares of CME Group from $270.00 to $261.00 in a research note to investors on Friday. They now have an “equal weight” rating on the stock. Separately, analysts at UBS AG (NYSE: UBS) cut their EPS estimates on shares of CME Group in a research note on Friday. They now have a “buy” rating and a $300.00 price target on the stock. They previously had a $330.00 price target on the stock. Finally, analysts at ISI Group cut their price target on shares of CME Group from $285.00 to $275.00 in a research note to investors on Friday.
CME Group Inc. (CME Group) offers a range of global products across all asset classes based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, metals, weather and real estate.